AbbVie Inc (ABBV) Given Average Rating of “Buy” by Analysts

Shares of AbbVie Inc (NYSE:ABBV) have received an average rating of “Buy” from the nineteen research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $119.22.

ABBV has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of AbbVie from a “hold” rating to a “buy” rating and set a $102.00 target price on the stock in a research note on Tuesday, October 17th. BidaskClub downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 25th. Vetr raised shares of AbbVie from a “buy” rating to a “strong-buy” rating and set a $113.08 price target on the stock in a research note on Wednesday, December 20th. Credit Suisse Group set a $98.00 price target on shares of AbbVie and gave the stock a “hold” rating in a research note on Monday, January 22nd. Finally, SunTrust Banks reissued a “buy” rating on shares of AbbVie in a research note on Monday, October 30th.

Shares of AbbVie (NYSE ABBV) traded up $2.75 on Tuesday, reaching $112.26. 10,462,179 shares of the company were exchanged, compared to its average volume of 7,199,267. The stock has a market capitalization of $178,350.00, a P/E ratio of 27.16, a P/E/G ratio of 1.09 and a beta of 1.61. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32. AbbVie has a 1-year low of $60.05 and a 1-year high of $125.86.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, January 26th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.44 by $0.04. The business had revenue of $7.74 billion for the quarter, compared to the consensus estimate of $7.53 billion. AbbVie had a net margin of 18.82% and a return on equity of 152.78%. AbbVie’s quarterly revenue was up 13.9% on a year-over-year basis. During the same period last year, the firm posted $1.20 earnings per share. research analysts anticipate that AbbVie will post 7.46 EPS for the current year.

In related news, EVP Michael Severino sold 25,633 shares of AbbVie stock in a transaction on Friday, November 10th. The shares were sold at an average price of $94.69, for a total value of $2,427,188.77. Following the transaction, the executive vice president now directly owns 114,922 shares of the company’s stock, valued at $10,881,964.18. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Timothy J. Richmond sold 87,040 shares of AbbVie stock in a transaction on Monday, December 18th. The stock was sold at an average price of $98.45, for a total transaction of $8,569,088.00. Following the completion of the transaction, the senior vice president now directly owns 113,118 shares in the company, valued at $11,136,467.10. The disclosure for this sale can be found here. Insiders have sold 476,376 shares of company stock worth $45,580,873 over the last three months. Insiders own 0.23% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of ABBV. Formidable Asset Management LLC boosted its holdings in AbbVie by 0.3% in the second quarter. Formidable Asset Management LLC now owns 3,926 shares of the company’s stock valued at $285,000 after acquiring an additional 10 shares in the last quarter. WealthTrust Axiom LLC boosted its holdings in AbbVie by 0.3% in the second quarter. WealthTrust Axiom LLC now owns 4,307 shares of the company’s stock valued at $312,000 after acquiring an additional 15 shares in the last quarter. St. Louis Trust Co boosted its holdings in AbbVie by 0.7% in the second quarter. St. Louis Trust Co now owns 3,411 shares of the company’s stock valued at $248,000 after acquiring an additional 23 shares in the last quarter. TRUE Private Wealth Advisors boosted its holdings in AbbVie by 0.6% in the second quarter. TRUE Private Wealth Advisors now owns 4,814 shares of the company’s stock valued at $349,000 after acquiring an additional 27 shares in the last quarter. Finally, Aspen Investment Management Inc boosted its holdings in AbbVie by 0.8% in the second quarter. Aspen Investment Management Inc now owns 5,210 shares of the company’s stock valued at $378,000 after acquiring an additional 40 shares in the last quarter. 69.54% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “AbbVie Inc (ABBV) Given Average Rating of “Buy” by Analysts” was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/02/06/abbvie-inc-abbv-given-average-rating-of-buy-by-analysts.html.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply